# A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma

> **NCT02998047** · PHASE1 · TERMINATED · sponsor: **Actinium Pharmaceuticals** · enrollment: 2 (actual)

## Conditions studied

- Refractory Multiple Myeloma

## Interventions

- **DRUG:** Lintuzumab AC 225

## Key facts

- **NCT ID:** NCT02998047
- **Lead sponsor:** Actinium Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-12
- **Primary completion:** 2020-05
- **Final completion:** 2020-05
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Poor recruitment
- **Last updated:** 2022-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02998047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02998047, "A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02998047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*